Document Detail

Increasing throughput in lead optimization in vivo toxicity screens.
MedLine Citation:
PMID:  11865675     Owner:  NLM     Status:  MEDLINE    
Lead optimization requires toxicity screening strategies to select a compound with a high likelihood of successful development. As numerous compounds need to be screened and resources to direct toward any single compound are limited, short turnaround times to generate and interpret data are needed. Utilization of in vivo toxicity screens is necessary for an effective screening strategy, however, if not appropriately implemented, they may consume excessive resources and prolong selection of a developable compound. Optimization of in vivo studies requires identifying effective placement into the screening strategy, selecting the appropriate study designs, implementing processes that allow rapid data generation and interpretation, and understanding the utilities of in vivo data. When implemented, an effective, high-throughput screening strategy will utilize adequate but minimal amounts of resources, and will prioritize processing near technical time limits. These require generating only the data from which decisions will be made and can be best achieved using as few animals as possible per study.
Vincent Meador; William Jordan; John Zimmermann
Related Documents :
19571415 - Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
17595425 - Design-related bias in hospital fall risk screening tool predictive accuracy evaluation...
3945055 - Applications of computerized interactive morphometry in pathology: i. tracings and gene...
20161245 - Online phenotype discovery based on minimum classification error model.
2344315 - Validation of prognostic models in primary biliary cirrhosis.
19964185 - Optimizing energy expenditure detection in human metabolic chambers.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in drug discovery & development     Volume:  5     ISSN:  1367-6733     ISO Abbreviation:  Curr Opin Drug Discov Devel     Publication Date:  2002 Jan 
Date Detail:
Created Date:  2002-02-27     Completed Date:  2002-08-12     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  100887519     Medline TA:  Curr Opin Drug Discov Devel     Country:  England    
Other Details:
Languages:  eng     Pagination:  72-8     Citation Subset:  IM    
Eli Lilly & Company, Greenfield Laboratories, 2001 East Main Street, Greenfield, IN 46140, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combinatorial Chemistry Techniques / methods
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical / methods*
Toxicology / methods*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravenous administration of poorly soluble new drug entities in early drug discovery: the potentia...
Next Document:  Gene expression profiling for pharmaceutical toxicology screening.